• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lamotrigine for chronic neuropathic pain and fibromyalgia in adults.
CONCLUSIONS: Large, high-quality, long-duration studies reporting clinically useful levels of pain relief for individual participants provided no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of about 200 to 400 mg daily. Given the availability of more effective treatments including antiepileptics and antidepressant medicines, lamotrigine does not have a significant place in therapy based on the available evidence. The adverse effect profile of lamotrigine is also of concern. PMID: 24297457 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 3, 2013 Category: Journals (General) Authors: Wiffen PJ, Derry S, Moore RA Tags: Cochrane Database Syst Rev Source Type: research

Parenteral anticoagulation in ambulatory patients with cancer.
CONCLUSIONS: Heparin may have a small effect on mortality at 12 months and 24 months. It is associated with a reduction in venous thromboembolism and a likely increase in minor bleeding. Future research should further investigate the survival benefit of different types of anticoagulants in patients with different types and stages of cancer. The decision for a patient with cancer to start heparin therapy for survival benefit should balance the benefits and downsides, and should integrate the patient's values and preferences. PMID: 25491949 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 10, 2014 Category: Journals (General) Authors: Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, Schünemann H Tags: Cochrane Database Syst Rev Source Type: research